A combined effort of 11 laboratories in the WHO African region to improve quality of Buruli ulcer PCR diagnosis: The "BU-LABNET".


Journal

PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488

Informations de publication

Date de publication:
11 2022
Historique:
received: 03 07 2022
accepted: 24 10 2022
revised: 16 11 2022
pubmed: 5 11 2022
medline: 19 11 2022
entrez: 4 11 2022
Statut: epublish

Résumé

Buruli ulcer is one of the 20 neglected tropical diseases in the world. This necrotizing hypodermitis is a chronic debilitating disease caused by an environmental Mycobacterium ulcerans. At least 33 countries with tropical, subtropical and temperate climates have reported Buruli ulcer in African countries, South America and Western Pacific regions. Majority of cases are spread across West and Central Africa. The mode of transmission is unclear, hindering the implementation of adequate prevention for the population. Currently, early diagnosis and treatment are crucial to minimizing morbidity, costs and preventing long-term disability. Biological confirmation of clinical diagnosis of Buruli ulcer is essential before starting chemotherapy. Indeed, differential diagnosis are numerous and Buruli ulcer has varying clinical presentations. Up to now, the gold standard biological confirmation is the quantitative PCR, targeting the insertion sequence IS2404 of M. ulcerans performed on cutaneous samples. Due to the low PCR confirmation rate in endemic African countries (under 30% in 2018) for numerous identified reasons within this article, 11 laboratories decided to combine their efforts to create the network "BU-LABNET" in 2019. The first step of the network was to harmonize the procedures and ship specific reagents to each laboratory. With this system in place, implementation of these procedures for testing and follow-up was easy and the laboratories were able to carry out their first quality control with a very high success rate. It is now time to integrate other neglected tropical diseases to this platform, such as yaws or leprosy.

Identifiants

pubmed: 36331971
doi: 10.1371/journal.pntd.0010908
pii: PNTD-D-22-00870
pmc: PMC9668193
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0010908

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright: © 2022 Marion et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist

Références

PLoS Negl Trop Dis. 2016 Apr 13;10(4):e0004385
pubmed: 27074157
PLoS One. 2014 Feb 21;9(2):e89407
pubmed: 24586755
Lancet. 2020 Apr 18;395(10232):1259-1267
pubmed: 32171422
Diagnostics (Basel). 2019 Nov 26;9(4):
pubmed: 31779247
J Clin Microbiol. 2014 Dec;52(12):4398-400
pubmed: 25320228
Methods Mol Biol. 2013;943:201-16
pubmed: 23104291
Lancet Glob Health. 2019 Jul;7(7):e912-e922
pubmed: 31200890
Appl Environ Microbiol. 2007 Aug;73(15):4733-40
pubmed: 17526786
Clin Infect Dis. 2011 Jan 1;52(1):94-6
pubmed: 21148526
J Clin Microbiol. 2012 Apr;50(4):1195-8
pubmed: 22259213
J Clin Microbiol. 2003 Sep;41(9):4231-7
pubmed: 12958250
PLoS Negl Trop Dis. 2021 Mar 3;15(3):e0009157
pubmed: 33657104

Auteurs

Estelle Marion (E)

Univ Angers, Nantes Université, INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Angers, France.

Numfor Hycenth (N)

BU-LABNET coordination center, Centre Pasteur du Cameroun, Yaoundé, Cameroun.

Sundeep Chaitanya Vedithi (SC)

Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom & American Leprosy Missions, Greenville, South Caroline, United States of America.

Marie Robbe-Saule (M)

Univ Angers, Nantes Université, INSERM, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302, Angers, France.

Valérie Donkeng (V)

Mycobacteriology service, Centre Pasteur du Cameroun, Yaoundé, Cameroun.

Line-Marlène Ganlonon (LM)

Centre de Diagnostic et de Traitement de la lèpre et de l'Ulcère de Buruli (CDTLUB)/Raoul et Madeleine Follereau, Pobè, Benin.

Affolabi Dissou (A)

Laboratoire de Référence des Mycobactéries, Cotonou, Benin.

Solange Kakou Ngazoa (SK)

Institut Pasteur, Abidjan, Cote d'Ivoire.

Marie-Jose Kabedi (MJ)

Institut National de Recherche Biomédicale, Kinshasa, Rép D. Congo.

Arsène Mabika Mabika (A)

Unité de Bactériologie, CIRMF, Franceville, Gabon.

Richard Phillips (R)

Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

Michael Frimpong (M)

Kumasi Centre for Collaborative Research in Tropical Medicine, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana.

Dorothy Yeboah-Manu (D)

Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.

Vera Yatta Walker (VY)

National Public Health Reference Laboratory, Liberia Institute of Biomedical Research Charlesville, Liberia.

Olaoluwa Akinwale (O)

Nigerian Institute of Medical Research, Lagos State, Nigeria.

Maman Issaka (M)

Institut Nationale d'Hygiene, Laboratoire de Biologie Moléculaire, Lomé, Togo.

Gisela Bretzel (G)

Division of Infectious Diseases and Tropical Medicine, Ludwig-Maximilians University Munich, Germany.

Kingsley Asiedu (K)

Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.

Sara Eyangoh (S)

BU-LABNET coordination center, Centre Pasteur du Cameroun, Yaoundé, Cameroun.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH